OptimizeRx Corporation earnings
Shares surged 26.9% following Q2 results that beat revenue and adjusted EBITDA expectations, driven by ongoing margin expansion and strong commercial momentum in AI-enabled offerings and platform innovation.
- Q2 revenue reached $20.5 million with adjusted EBITDA of $4.9 million, both surpassing consensus estimates.
- Despite some revenue declines from a few large customers transitioning away from lower-margin services, growth was evident across the broader business.
- AI-enabled software subscriptions grew 25% year-over-year, underscoring a successful shift toward recurring revenue models.
Next report: March 4, 2027 (estimated) · Earnings calendar
Every OPRX quarter
2 quarters, newest first, with how the stock moved after each report.
| Quarter | Reported | Stock after | What happened |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | +26.9% | Shares surged 26.9% following Q2 results that beat revenue and adjusted EBITDA expectations, driven by ongoing margin expansion and strong commercial momentum in AI-enabled offerings and platform innovation. |
| Q3 2025 | Nov 7, 2025 | Not available | OptimizeRx reported a robust Q3 2025 with revenues of $26.1 million, reflecting a 22% year-over-year growth, and an adjusted EBITDA of $5.1 million, exceeding expectations. |
Shares surged 26.9% following Q2 results that beat revenue and adjusted EBITDA expectations, driven by ongoing margin expansion and strong commercial momentum in AI-enabled offerings and platform innovation.
Q3 2025Nov 7, 2025OptimizeRx reported a robust Q3 2025 with revenues of $26.1 million, reflecting a 22% year-over-year growth, and an adjusted EBITDA of $5.1 million, exceeding expectations.
Track earnings for the stocks you own
Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.